Isatuximab-Irfc Combination Approved for Multiple Myeloma

The FDA has approved isatuximab-irfc (Sarclisa®, Sanofi) in combination with carfilzomib and dexamethasone (Kd), for adult patients with relapsed or refractory multiple myeloma who have previously received one to three lines of therapy. "Treatment of relapsed/refractory multiple myeloma (RRMM) has greatly improved, yet relapse is inevitable and additional effective treatments are needed," wrote Philippe Moreau, MD, Head of the Hematology Department at the University Hospital of Nantes in France,...
Continue reading


Get the latest updates delivered to your inbox!

Follow Us

Copyright ┬ę 2021 Oncology Data Advisor. All rights reserved.